Fecha de publicación:
28 de septiembre de 2022

Tiempo de lectura:
07:30 MIN

    1. Cranmer LD, Engelhardt C, and Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010; 15:1320-1328.

    2. Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015;51:1989-2007.

    3. Karia PS, Han J, and Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013;68:957-966.

    4. American Cancer Society. What are basal and squamous cell skin cancers? 2019; Available at: https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer/about/what-is-basal-and-squamous-cell.html. Acceso 23 April 2019.

    5. Burton KA, Ashack KA, and Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. Am J Clin Dermatol 2016;17:491-508.

    6. Newlands C, Currie R, Memon A, et al. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130:S125-S132.

    7. Amolis M, Lee CS, Sunwoo J, et al. Node-positive cutaneous squamous cell carcinoma of the head and neck: survival, high- risk features, and adjuvant chemoradiotherapy outcomes. Head Neck 2017;39:881-885.

    8. Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015;151:1081-1086.

    9. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010;146:283-287.

    10. Waldman A and Schmults C. Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am 2019;33:1-12.

    11. Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol 2005;23:759-765.

    12. Stratigos A, Garbe C, Lebbe C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin. Eur J Cancer 2019.

    13. Arunachalam D, Thirumoorthy A, Devi S, et al. Quality of life in cancer patients with disfigurement due to cancer and its treatments. Indian J Palliat Care 2011;17:184-190.

    14. Berens AM, Akkina SR, and Patel SA. Complications in facial Mohs defect reconstruction. Curr Opin Otolaryngol Head Neck Surg 2017;25:258-264.

    15. Karia PS, Jambusaria-Pahlajani A, Harrington DP, et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 2014;32:327-334.

    16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Squamous cell skin cancer. Version 1.2020 - October 2, 2019.

    17. Parikh SA, Patel VA, and Ratner D. Advances in the management of cutaneous squamous cell carcinoma. F1000Prime Rep 2014;6:70.

    18. Rhee JS, Matthews BA, Neuburg M, et al. Creation of a quality of life instrument for nonmelanoma skin cancer patients. Laryngoscope 2005;115:1178-1185.

    19. Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th ed. 2017: Springer Nature, Switzerland.

    20. Brierley JD, Gospodarowicz MK, and Wittekind CE. TNM Classification of Malignant Tumours, 8th Edition. 2016: Wiley.

    21. Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 2013;149:402-410.

    22. Ascierto PA and Schadendorf D. Immunotherapy in non-melanoma skin cancer: updates and new perspectives. Drugs Context 2019;8:212583.

    23. Hillen U, Leiter U, Haase S, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer 2018;96:34-43.

    24. Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018;379:341-351.

    25. Rowe DE, Carroll RJ, and Day CL, Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992;26:976-990.

    26. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9:34.

    27. Pickering CR, Zhou JH, Lee JJ, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 2014;20:6582-6592.

    28. Economopoulou P, Kotsantis I, and Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open 2016;1:e000122.

    29. Thompson LDR. Squamous cell carcinoma variants of the head and neck. Curr Diag Path 2003;9:384-396.

    30. Alam M, Armstrong A, Baum C, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol 2018;78:560-578.

    31. Sacco AG and Daniels GA. Adjuvant and neoadjuvant treatment of skin cancer. Facial Plast Surg Clin North Am 2019;27:139- 150.

    32. Targeted Oncology. The current and future treatment landscape of cutaneous squamous cell carcinoma. 2018; Available at: https://www.targetedonc.com/publications/evolving-paradigms/2018/cutaneous-squamous-cell-carcinoma/the-current-and-future-treatment-landscape-of-cutaneous-squamous-cell-carcinoma. Accessed 21 June 2019.

    33. Stratigos A, Garbe C, Lebbe C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin. Eur J Cancer 2019


Temas relacionados

Fill out my online form.

Actualidad Científica

Cáncer cutáneo

Actualiza tus conocimento en Cáncer cutáneo